American Diabetes Association. Standards
of medical care in diabetes—2006 [position statement]. Diabetes
Care.2006;29:
S4-S42.
2.
American Diabetes Association. Diabetes in the
Latino population: a case-based approach to optimal management [slide presentation].
Available at: www.diabetes.org. Accessed August 29, 2006.
3.
Thom T, Haase N, Rosamond W, et al.Heart disease and stroke
statistics—2006 update: a report from the American Heart Association Statistics Committee and Stroke
Statistics Subcommittee.
Circulation.2006;113:
e85-e151.
4.
Shai I, Jiang R, Manson JE, et al.Ethnicity, obesity, and risk of type
2 diabetes in women: a 20-year follow-up study. Diabetes
Care.2006;29:
1585-1590.
5.
Luna B, Feinglos MN.Oral agents in the management
of type 2 diabetes mellitus. Am Fam
Physician.2001;63: 1747-1756,
1759-1780.
6.
Riddle MC, Drucker DJ.Emerging therapies mimicking
the effects of amylin and glucagon-like peptide 1. Diabetes
Care.2006;29:
435-449.
7.
Humalog [package insert]. Indianapolis, Ind: Eli Lilly and
Company; 2004.
8.
Boden G, Zhang M.Recent findings concerning
thiazolidinediones in the treatment of diabetes. Expert Opin Investig
Drugs.2006;15:
243-250.
9.
Therapeutic Research Center. Oral
combination products for type 2 diabetes. Pharmacist’s Letter/Prescriber’s
Letter.2006;22(220206):
1-3.
10.
Turner RC, Cull CA, Frighi V, Holman RR, for the UK Prospective Diabetes Study
Group. Glycemic control with diet, sulfonylurea,
metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for
multiple therapies (UKPDS 49).
JAMA.1999;281:
2005-2012.
11.
Therapeutic Research Center.
Investigational medicines for diabetes: sitagliptin (Januvia) and vildagliptin
(Galvus). Pharmacist’s Letter/Prescriber’s
Letter.2006;22(220715):
1-3.
12.
Holst JJ.Glucagon-like peptide-1: from
extract to agent.
Diabetologia.2006;49:
253-260.
13.
Daily G.New strategies for basal insulin
treatment in type 2 diabetes mellitus. Clin
Ther.2004;26:
889-901.
14.
Therapeutic Research Center. Comparison of
insulins. Pharmacist’s Letter/Prescriber’s
Letter.2006;22(220309):
1-11.
15.
Therapeutic Research Center. Insulin for
oral inhalation (Exubera). Pharmacist’s Letter/Prescriber’s
Letter.2006;22(220701):
1-5.
16.
Symlin [package insert]. San Diego, Calif: Amylin
Pharmaceuticals; 2005.
17.
Hollander PA, Levy P, Fineman MS, et al.Pramlintide as an adjunct to insulin
therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year
randomized controlled trial. Diabetes
Care.2003;26:
784-790.
18.
Byetta [package insert]. San Diego, Calif: Amylin
Pharmaceuticals; 2006.
19.
Wagner J, Lacey K, Abbott G, de Groot M, Chyun D.Knowledge of heart disease risk in
a multicultural community sample of people with diabetes. Ann Behav
Med.2006;31:
224-230.
20.
American Diabetes Association, American College of Cardiology.
The diabetes-heart disease link: surveying attitudes, knowledge and risk [executive
summary]. Available at: www.diabetes.org/type-1-diabetes/wellbeing/link-healthprof.jsp.
Accessed August 29, 2006.
21.
Piette
JD, Glasgow
RE.Education and home glucose
monitoring. In: Gerstein
HC, Haynes
R, eds. Evidence-Based Diabetes Care.
Hamilton, Canada: BC Decker;
2001:207-251.
22.
Anderson RM, Funnell MM.Patient empowerment:
reflections on the challenge of fostering the adoption of a new paradigm.
Patient Educ Couns.2005;57:
153-157.
23.
Glasgow RE, Davis CL, Funnell MM, Beck A.Implementing practical
interventions to support chronic illness self-management. Jt Comm J Qual
Saf.2003;29:
563-574.
24.
American Association of Diabetes Educators.
Individualization of diabetes self-management education [position statement].
November 2002. Available at:
http://www.aadenet.orgAboutUs/PositionStateIndex.shtml. Accessed August 29,
2006.
25.
Del
Prato S, Felton
A, Munro
N, Nesto
R, Zimmet
P, Zinman
B, for the Global
Partnership for Effective Diabetes Management. Improving
glucose management: ten steps to get more patients with type 2 diabetes to glycaemic
goal. Int J Clin Pract.2005;59:
1345-1355.
